The company appears to be preparing investors for less than ideal results for its DNA vaccine VGX-3100, which is in phase 2 trials to treat women who have cervical precancerous cells. Our stock soared after a 4-1 reverse split Friday and the announcement this week of a new trial for immune therapy to treat neck and head cancers. Then it began tumbling after the company’s CEO gave an interview that seemed to be backpedaling expectations.
↧